Korean drug Agency OKs local trial of innovative osteoporosis drug

Published: 2009-10-28 06:56:00

Updated: 2009-10-28 06:56:00

Helixer Co., a local biopharmaceutical company, said on October 26 that it has received approval from the Korean Food and Drug Administration to conduct Phase 3 clinical trial of a drug, PG201, for the treatment of osteoporosis.

The company said the approval comes after successful completion o...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK